Table 13.

Characteristics of Randomized Clinical Trials by Reuse of Prospective Data

Characteristic	Absence of reuse of prospective data, No. (%)	Presence of reuse of prospective data, No. (%)	Total, No. (%)	P
Time of registration
2003–2013.06	66 (70.97)	15 (62.50)	81 (69.23)	0.423
2013.06–2023	27 (29.03)	9 (37.50)	36 (30.77)
Primary purpose
Treatment	80 (86.02)	19 (79.17)	99 (84.62)	0.474
Other	12 (12.90)	5 (20.83)	17 (14.53)
Prevent	1 (1.08)	0 (0.00)	1 (0.85)
Intervention
Pharmacological	66 (70.97)	16 (66.67)	82 (70.09)	0.682
Nonpharmacological	27 (29.03)	8 (33.33)	35 (29.91)
Intervention model
Crossover	12 (12.90)	7 (29.17)	19 (16.24)	0.128
Parallel	80 (86.02)	17 (70.83)	97 (82.91)
Factorial	1 (1.08)	0 (0.00)	1 (0.85)
Arm
2	74 (79.57)	20 (83.33)	94 (80.34)	0.795
3	14 (15.05)	4 (16.67)	18 (15.38)
≥4	5 (5.38)	0 (0.00)	5 (4.27)
Blinding
None or open label	25 (26.88)	9 (37.50)	34 (29.06)	0.665
Single	10 (10.75)	2 (8.33)	12 (10.26)
Double or more	58 (62.37)	13 (54.17)	71 (60.68)
Funder type
None or departmental	47 (50.54)	15 (62.50)	62 (52.99)	0.295
Industry or other  external	46 (49.46)	9 (37.50)	55 (47.01)
Recruitment
Single center	35 (37.63)	11 (45.83)	46 (39.32)	0.538
Multicenter	55 (59.14)	13 (54.17)	68 (58.12)
Missing	3 (3.23)	0 (0.00)	3 (2.56)
No. of participants
<350	65 (69.89)	16 (66.67)	81 (69.23)	0.760
≥350	28 (30.11)	8 (33.33)	36 (30.77)
PI region
Nonhigh SDI	22 (23.66)	3 (12.50)	25 (21.37)	0.235
High SDI	71 (76.34)	21 (87.50)	92 (78.63)
PI region
<90	79 (84.95)	21 (87.50)	100 (85.47)	1.000
≥90	14 (15.05)	3 (12.50)	17(14.53)
PI region
High income	75 (80.65)	21 (87.50)	96 (82.05)	0.560
Nonhigh income	18 (19.35)	3 (12.50)	21 (17.95)
PI region
North America	32 (34.41)	10 (41.67)	42 (35.90)	0.521
Europe	22 (23.66)	7 (29.17)	29 (24.79)
Other	39 (41.94)	7 (29.17)	46 (39.32)

^*P < 0.05